Finding 570663 (2024-004)

Material Weakness Repeat Finding
Requirement
L
Questioned Costs
-
Year
2024
Accepted
2025-07-08
Audit: 361681
Organization: Tuerk House, Inc. (MD)

AI Summary

  • Core Issue: The Organization's annual expenditure reporting did not match the actual grant expenditures, and quarterly programmatic reports were inaccurately completed.
  • Impacted Requirements: Compliance with reporting standards under 45 CFR 75.342 was not met due to lack of internal controls.
  • Recommended Follow-Up: Management should implement a review process for report accuracy before submission to ensure all reported amounts are supported by proper documentation.

Finding Text

Opioid STR ALN No. 93.788 U.S. Department of Health and Human Services Criteria or Specific Requirement – Reporting (45 CFR 75.342) Condition – The Organization’s annual expenditure reporting did not agree to the underlying grant expenditure support. In addition, the Organization did not properly report certain information in its quarterly programmatic reports. Cause – The Organization did not have necessary internal controls to properly identify and report eligible grant expenditures. In addition, the Organization did not have controls in place to support amounts reported in quarterly programmatic reporting requirements. Effect or potential effect– The Organization incorrectly reported grant expenditures and programmatic statistics, such as total unique patients. Questioned Costs – None Context – A sample of one financial report was tested out of the total population of 2 financial reports. In addition, a sample of one special report was tested out of the total population of 4 special reports. The sampling methodology used is not and is not intended to be statistically valid. Certain amounts on the financial and special reports were not accurately reported. Identification as a repeat finding, if applicable – Repeat finding (see 2022-005 and 2023-005) Recommendation – Management should review the required reports for accuracy prior to submission to ensure the documentation supports the amounts in the report.

Corrective Action Plan

Tuerk House, Inc. acknowledges the finding related to the accuracy of financial and programmatic reporting. We recognize the critical importance of maintaining accurate and supportable reporting for federal awards, particularly in light of this being a repeat finding. In response, Tuerk House has initiated corrective actions to improve internal controls over financial and programmatic reporting. These actions include: ·Establishing a standardized reconciliation process to ensure that all amounts reported in financial reports are tied directly to supporting documentation from the general ledger and other internal financial systems. ·Implementing a dual-review protocol requiring reports to be reviewed and approved by both finance and program staff before submission to funding agencies. · Providing targeted training to relevant personnel on grant reporting requirements, with an emphasis on reporting accuracy, documentation standards, and deadlines. ·Coordinating regular meetings between finance and program departments to align data and ensure consistency between financial and programmatic reporting (e.g., patient counts, service metrics, etc.). ·Developing a reporting calendar to track all reporting requirements and facilitate timely and accurate submissions. We are committed to ensuring accurate and compliant reporting going forward and will monitor implementation closely to prevent recurrence. Organization Contact Person Responsible for Corrective Action – Joseph Koehler, Director of Finance Anticipated Completion Date – June 30, 2025

Categories

Reporting Internal Control / Segregation of Duties

Other Findings in this Audit

  • 570660 2024-002
    Material Weakness Repeat
  • 570661 2024-002
    Material Weakness Repeat
  • 570662 2024-003
    Material Weakness Repeat
  • 1147102 2024-002
    Material Weakness Repeat
  • 1147103 2024-002
    Material Weakness Repeat
  • 1147104 2024-003
    Material Weakness Repeat
  • 1147105 2024-004
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
93.788 Opioid Str $2.67M
93.959 Block Grants for Prevention and Treatment of Substance Abuse $1.23M
95.007 Research and Data Analysis $208,650
21.019 Coronavirus Relief Fund $10,199